drugset
drugset / Trial / NCT07025889

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

NCT07025889 ↗

Phase 1/2 Recruiting 55 enrolled Ruijin Hospital Shanghai Jiao Tong University School of Medicine · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Timeline

Start
2025-06-02
Primary completion
2026-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI343 Monoclonal antibody 3 mg/kg Intravenous
Subject IBI343 Monoclonal antibody 4.5 mg/kg Intravenous
Subject IBI343 Monoclonal antibody 6 mg/kg Intravenous
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous
Background S-1 Small molecule 40 mg Oral
Background S-1 Small molecule 60 mg Oral
Background Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

gastric cancer